Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Product” of 2025 ...

SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Regeneron Pharmaceuticals, Inc. ( REGN ), the Tarrytown, New York headquartered Pharma company, reported its Q3 earnings yesterday. Its stock surged as revenues of $3.75bn, and earnings per share of $11.83 on a nor ...

公司业绩表现 - 再生元制药公布第三季度财报 营收达到37.5亿美元 每股收益为11.83美元（标准化基础）和13.62美元（按报告基础）[1] - 财报公布后公司股价出现大幅上涨[1] 作者背景与服务 - 文章作者为生物技术顾问 在生物技术、医疗保健和制药行业拥有超过5年研究经验 并对超过1000家公司完成详细报告[1] - 其投资平台Haggerston BioHealth提供每周通讯订阅服务 内容涵盖行业动态、关键催化剂、买卖评级、产品销售预测、综合财务报表、现金流折现分析和市场分析[1] - 该平台服务对象包括生物科技投资新手和经验丰富的投资者[1]

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.He leads the investing group Growth Stock Forum which features: a model portfolio of 15-2 ...

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multispecific antibodies for several therapeutic indications of mutual intere ...

Key Takeaways Regeneron posted Q3 EPS of $11.83, topping estimates but down 5% from last year on higher costs.Revenues rose 1% to $3.7B, driven by Dupixent's 27% surge and Eylea HD's growing demand.Libtayo sales climbed 27%, while new oncology approvals strengthen Regeneron's therapeutic portfolio.Regeneron Pharmaceuticals, Inc. (REGN) reported third-quarter 2025 adjusted earnings per share (EPS) of $11.83, which comfortably beat the Zacks Consensus Estimate of $9.44. However, the bottom line was down 5% fr ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

By Christy Santhosh (Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending shares up 8%. The drugmaker said it will resubmit the marketing application for the pre-filled syringe version of higher-dose Eylea, or Eylea HD, after the U.S. Food and Drug Administration declined its approval on Monday. The company has been facing multiple regulatory setbacks due to t ...

Regeneron (REGN) reported $3.75 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 0.9%. EPS of $11.83 for the same period compares to $12.46 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.6 billion, representing a surprise of +4.38%. The company delivered an EPS surprise of +25.32%, with the consensus EPS estimate being $9.44.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...